Unicycive Therapeutics Inc (UNCY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $97.25M
Last updated: Nov 17, 2026 at 11:06 AM ET
Unicycive Therapeutics Inc (UNCY) Stock Forecast
Analysts expect Unicycive Therapeutics (UNCY) to earn -$1.27 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.37M. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 20.0% |
| Buy | 8 | 80.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 10044.5%.
- Fiscal year ending Dec 31, 2026
- -$1.27
- EPS consensus, revenue $1.37M
- Fiscal year ending Dec 31, 2027
- $1.45
- EPS consensus, revenue $138.98M
- Next report
- Mar 29, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.27 | -$1.61 to -$0.62 | 9 | $1.37M | N/A | 10 |
| Dec 31, 2027 | $1.45 | -$0.96 to $5.53 | 8 | $138.98M | $27.45M to $307.17M | 9 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.34 | -$0.42 to -$0.26 | 11 | $321004 | N/A | 11 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.50.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.27 | -$1.27 | -$1.23 | -$1.23 | -$1.50 | N/A |
| Fiscal year ending Dec 31, 2027 | $1.45 | $1.69 | $1.66 | $1.66 | $5.10 | -71.6% |
Frequently Asked Questions About UNCY
What is the UNCY stock forecast?
Consensus analyst estimates put Unicycive Therapeutics's EPS at -$1.27 for the fiscal year ending Dec 31, 2026, on revenue of $1.37M. The consensus rating from 10 analysts is Buy.
How do analysts rate UNCY stock?
Of 10 analysts covering Unicycive Therapeutics, 2 rate it Strong Buy, 8 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from UNCY next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.27, with estimates from -$1.61 to -$0.62 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.45, with estimates from -$0.96 to $5.53 from 8 analysts.
What revenue do analysts expect from Unicycive Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.37M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $138.98M, with estimates from $27.45M to $307.17M.
How many analysts cover UNCY?
10 analysts rate Unicycive Therapeutics stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
UNCY pages: Overview, Earnings, Forecast, Financials, Competitors